Figure 1.

A patient with a primary gastrointestinal stromal tumour in the colon. The pre-treatment CT scan (a) shows a peritoneal mass (arrows), corresponding to a lesion with markedly increased fludeoxyglucose (FDG) uptake on the positron emission tomography (PET) scan (b). The CT scan (c) obtained 2 months after treatment showed that the mass had become larger; however, there was no appreciable FDG uptake seen on the FDG PET scan (d), which corresponded to clinical improvement. Reproduced with permission from Choi et al [7].